Latest News
- January 08, 2026Official press release: CBCC Global Research is now REV Clinical
- November 18, 2025ANDA application for Bimatoprost ophthalmic solution received Marketing Authorization from the USFDA!
- November 12, 2025ANDA application for Risperidone extended-release injectable suspension has received Marketing Authorization from the USFDA!
- October 30, 2025Accelerating Clinical Research!
- September 12, 2025Join CBCC at CPHI Frankfurt 2025
November 18, 2025
ANDA application for Bimatoprost ophthalmic solution received Marketing Authorization from the USFDA!
ANDA application for Bimatoprost ophthalmic solution, managed by CBCC received Marketing Authorization from the USFDA!
Type of Study: Clinical endpoint
Therapeutic Area: Ophthalmology
Scope: End-to-end clinical trial management
Countries of Trial Execution: USA & India
CBCC Global Research: CHANGING LIVES THROUGH HOPE AND INNOVATION
Manoj Vyas Dr. Sandeep Singh Jaimeen Vanparia Sanjeev Ganatra Nikhil Gandhi Harakh Shah, PMP® Tapan Shah Kinnari Gandhi RQAP-GCP Dr Praveen Choudhary Nikunj Patel Ankit Parikh Ajit Upadhyaya Ankit Pandav Devang Pandya Jay Vyas Udayan Vyas
ClinicalResearch PharmaceuticalScience DrugDevelopment
ClinicalTrials PhaseITrial MedicalResearch